slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
BRAVER Trial PowerPoint Presentation
Download Presentation
BRAVER Trial

Loading in 2 Seconds...

play fullscreen
1 / 4

BRAVER Trial - PowerPoint PPT Presentation


  • 163 Views
  • Uploaded on

BR achial A rtery V ascular E ndothelium R eactivity Study A substudy of PROVE IT-TIMI 22. BRAVER Trial. BRAVER: Study design. Substudy of PROVE IT-TIMI 22. Objective: – Evaluate time course of improvement in endothelial function with statin after acute coronary syndromes (ACS)

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'BRAVER Trial' - yuma


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

BRachial Artery Vascular Endothelium Reactivity Study

A substudy of PROVE IT-TIMI 22

BRAVER Trial

slide2

BRAVER: Study design

Substudy of PROVE IT-TIMI 22

Objective: – Evaluate time course of improvement in endothelial function with statin after acute coronary syndromes (ACS)

– Compare effects of intense vs moderate statin therapies on vascular reactivity

Design: Randomized double-blind 2 x 2 factorial design

Population: N = 50 with ACS; total cholesterol ≤240 mg/dL*

Treatment: Atorvastatin 80 mg (n = 24) or pravastatin 40 mg (n = 26)

Outcome: Amount of change in brachial artery reactivity measured by high-resolution ultrasound at days 2, 30, and 120

*≤200 mg/dL if on long-term lipid-lowering drugs

BRachial Artery Vascular Endothelium Reactivity

Dupuis J et al. Am J Cardiol. 2005;96:1207-13.

slide3

BRAVER: Results

  • 32% reduction in LDL-C with atorvastatin 80 mg (P < 0.001 vs baseline) vs no reduction with pravastatin 40 mg after 4 months
  • Similar reductions in C-reactive protein (CRP) in both treatment groups
  • 27% increase in FMD; 24% increase in NMD (P <0.05 vs baseline), with no difference between treatment strategies
  • Changes in FMD, lipid levels, and CRP were not correlated
  • FMD and NMD remained unchanged in patients treated with statins prior to ACS (n = 15)

FMD = Endothelium-dependent flow-mediated dilation

NMD = Endothelium-independent sublingual nitroglycerin-mediated dilation

BRachial Artery Vascular Endothelium Reactivity

Dupuis J et al. Am J Cardiol. 2005;96:1207-13.

slide4

BRAVER: Clinical implications

  • Statin therapy soon after ACS improves endothelium-dependent and endothelium-independent vascular reactivity
  • Improvements observed after 4 months of treatment
  • Results comparable despite differing intensities of treatment
  • Power to detect differences between atorvastatin and pravastatin groups was limited; findings add to growing evidence that improvement in vascular reactivity with statins is independent of the importance of lowering cholesterol
  • Lack of improvement in subjects previously using statins suggests new statin initiation is needed for major improvements in vascular reactivity after ACS

BRachial Artery Vascular Endothelium Reactivity

Dupuis J et al. Am J Cardiol. 2005;96:1207-13.